Summary Dipeptidyl‐peptidase‐4 (DPP‐4) inhibitors, as the most recent available anti‐
diabetic agents, were generally used in clinical treatment of type 2 diabetes (T2 DM). In …

Introduction: Dipeptidyl peptidase-4 inhibitors increase circulating levels of glucagon-like
peptide 1 (GLP-1) and glucose dependent insulinotropic polypeptide regulating glucose …

Objective: A novel treatment option for diabetic patients is the enhancement of incretin
hormone activity by inhibition of the enzyme dipeptidyl peptidase‐4 (DPP‐4). This study was …

Inhibition of dipeptidyl peptidase-4 (DPP-4) as a novel therapy for type 2 diabetes is based
on prevention of the inactivation process of bioactive peptides, the most important in the …

Introduction Preliminary data suggest that dipeptidyl peptidase-4 (DPP-4) inhibitors may
reduce microvascular events, but there is a little evidence to support this from adequate real …

Aims To compare the effects of vildagliptin with those of glimepiride on glycaemic control, fat
tolerance and inflammatory markers in people with Type 2 diabetes mellitus receiving …

Background Patients with type 2 diabetes present with an accelerated atherosclerotic
process. Animal evidence indicates that dipeptidyl peptidase-4 inhibitors (gliptins) have anti …

Several new oral antidiabetic agents, known as 'gliptins' or 'enzyme dipeptidyl peptidase‐IV
(DPP‐4) inhibitors', have been developed for the treatment of type 2 diabetes and a key …

Objective: Metformin is widely used for treating patients with type 2 diabetes, often as first-
line therapy; however, many patients with type 2 diabetes are unable to maintain adequate …

Objectives Trigonelline (TRG) is known to have an antidiabetic efficacy; however, its
mechanism is not entirely elucidated. Methods Hence, its effect on insulin signaling, besides …